Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Zacks Jan 22 20:55

Oppenheimer Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $31

Futu NewsJan 22 07:31 · Ratings

Express News | Catalyst Pharmaceuticals Announces Sub-Licensee Dydo Pharma Launched Firdapse® in Japan

BreakingsJan 21 21:19

Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE in Japan

GlobeNewswireJan 21 21:19

Truist Financial Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating

Futu NewsJan 14 20:31 · Ratings

Are Robust Financials Driving The Recent Rally In Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock?

Simply Wall StJan 13 22:43